Description
E3 Ligand-linker Conjugate 5
| Catalog number: | B2012901 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 1 mg |
| Molecular Weight or Concentration: | 315.4 g/mol |
| Supplied as: | Lyophilized Powder |
| Applications: | molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | E3 Ligand linker Conjugate 5 |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Sosi I, Bricelj A, Steinebach C. E3 ligase ligand chemistries: from building blocks to protein degraders Chem Soc Rev. 2022 May 10;51(9):3487-3534.
- Bricelj A, Steinebach C, Kuchta R, Gtschow M, Sosi I. E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points Front Chem. 2021 Jul 5;9:707317.
- Wang C, Zhang Y, Wu Y, Xing D. Developments of CRBN-based PROTACs as potential therapeutic agents Eur J Med Chem. 2021 Dec 5;225:113749.
- Khan S, He Y, Zhang X, Yuan Y, Pu S, Kong Q, Zheng G, Zhou D. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics Oncogene. 2020 Jun;39(26):4909-4924.
- Scheepstra M, Hekking KFW, van Hijfte L, Folmer RHA. Bivalent Ligands for Protein Degradation in Drug Discovery Comput Struct Biotechnol J. 2019 Jan 25;17:160-176.
- Nieto-Jimnez C, Morafraile EC, Alonso-Moreno C, Ocaa A. Clinical considerations for the design of PROTACs in cancer Mol Cancer. 2022 Mar 7;21(1):67.
- Weng G, Shen C, Cao D, Gao J, Dong X, He Q, Yang B, Li D, Wu J, Hou T. PROTAC-DB: an online database of PROTACs Nucleic Acids Res. 2021 Jan 8;49(D1):D1381-D1387.
- Konstantinidou M, Li J, Zhang B, Wang Z, Shaabani S, Ter Brake F, Essa K, Dmling A. PROTACs- a game-changing technology Expert Opin Drug Discov. 2019 Dec;14(12):1255-1268.
- Guenette RG, Yang SW, Min J, Pei B, Potts PR. Target and tissue selectivity of PROTAC degraders Chem Soc Rev. 2022 Jul 18;51(14):5740-5756.
